Acute demyelinating optic neuritis.
Foroozan Rod, Buono Lawrence M, Savino Peter J, Sergott Robert C
AI Summary
Research on acute optic neuritis found interferon beta-1a reduced multiple sclerosis risk by 50% in high-risk patients, guiding current treatment to prevent MS progression.
Abstract
Acute demyelinating optic neuritis associated with multiple sclerosis (MS) is the most common cause of inflammation of the optic nerve. The Optic Neuritis Treatment Trial (ONTT) has provided important clinical data on the use of corticosteroids, and demonstrated that patients with characteristic inflammatory lesions within the brain on magnetic resonance imaging had a greater chance of developing clinically definite MS (CDMS). The current approach to patients with optic neuritis has been modified by the results of the Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS). Patients with an initial clinical episode of demyelination (optic neuritis, incomplete transverse myelitis, or brain-stem/cerebellar syndrome) and at least two characteristic demyelinating lesions within the brain were randomized to receive interferon beta-1a or placebo after initial treatment with intravenous corticosteroids. At the 3-year point patients treated with interferon beta-1a showed a 50% less risk of CDMS. The results of this study have set the standard for patients with a first bout of demyelinating optic neuritis.
MeSH Terms
Shields Classification
Related Articles5
Addressing neurodegeneration in glaucoma: Mechanisms, challenges, and treatments.
ReviewTelmisartan Reduces Axon Degeneration in Mice With Experimental Glaucoma.
Basic ScienceOrbital disease in neuro-ophthalmology.
ReviewNeuroprotection in Optic Neuropathy.
ReviewCurrent understanding of neuroprotection in glaucoma.
ReviewIs this article assigned to the wrong chapter(s)? Let us know.